Impact of blood donation biovigilance and transfusion‐transmitted infections on organ transplantation DOI
Adam G. Stewart, Camille N. Kotton

Transplant Infectious Disease, Journal Year: 2024, Volume and Issue: 26(S1)

Published: June 27, 2024

Over 118 million blood donations are collected globally each year. Recipients of products include those who experience major trauma or surgery, have acute loss and anemia, impaired bone marrow function. Solid organ transplant recipients often require transfusion which places them at risk transfusion-associated adverse events including transfusion-transmitted infection. National hemovigilance networks documented low rates infection in the general population. Incidence continues to occur solid patients arises mainly from existing gaps donor biovigilance processes. Emerging infectious diseases highlighted donor-recipient pathway administering safe products. This article reviews current process regulatory oversight biovigilance, screening microbiological testing, highlights cases literature, addresses ways may be improved, with a focus on impact transplantation.

Language: Английский

Concerns regarding Transfusions of Blood Products Derived from Genetic Vaccine Recipients and Proposals for Specific Measures DOI Open Access
Jun Ueda, Hideyuki Motohashi,

Yuriko Hirai

et al.

Published: March 15, 2024

The coronavirus pandemic was declared by the World Health Organization (WHO) in 2020, and a global genetic vaccination program has been rapidly implemented as fundamental solution. However, many countries around world have reported that so-called vaccines, such those using modified mRNA encoding spike protein lipid nanoparticles drug delivery system, resulted post-vaccination thrombosis subsequent cardiovascular damage, well wide variety of diseases involving all organs systems, including nervous system. In this article, based on these circumstances volume evidence recently come to light, we call attention medical professionals various risks associated with blood transfusions products derived from people who suffered long COVID vaccine recipients, received make proposals regarding specific tests, testing methods, regulations deal risks. We expect proposal will serve basis for discussion how address syndrome its consequences following programs.

Language: Английский

Citations

1
Transfusions of Blood Products Derived from Genetic Vaccine Recipients: Safety Concerns and Proposals for Specific Measures DOI Open Access
Jun Ueda, Hideyuki Motohashi,

Yuriko Hirai

et al.

Published: May 29, 2024

The World Health Organization declared the coronavirus disease 2019 (COVID-19) pandemic in 2020, following which a global genetic vaccination program has been rapidly implemented as fundamental solution. However, it reported worldwide that modified mRNAs encoding spike proteins and lipid nanoparticles, are used drug delivery systems, not only cause thrombosis cardiovascular disorders post vaccination, but might also diverse diseases involving all organs including nervous system. Furthermore, toxicity pathogenicity of may necessitate defining these nonbiological infective material. Based on reports abundant evidence come to light past few years, this paper aims draw attention medical professionals various risks associated with transfusion using blood products derived from long COVID patients or vaccine recipients, make proposals regarding specific inspection items, testing methods, regulations, etc. This provides insights address post-vaccination syndrome its consequences such programs.

Language: Английский

Citations

1
Perspectives on donor‐derived infections from Germany DOI

Ana Paula Barreiros,

Klaus Böhler,

Kerstin Mönch

et al.

Transplant Infectious Disease, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 23, 2024

Often, organ transplantation is the only option to improve life expectancy and quality of patients with terminal failure. Despite improved donor assessment, a residual risk remains for transmitting infection, tumor, or other disease from recipients. Analysis, reporting, managing donor-derived diseases through vigilance surveillance system (V&S) mandatory in many countries. We report on suspected proven/probable infections (DDI) Germany over period 8 years (2016-2023).

Language: Английский

Citations

1
Identifying CNS infections in transplantation and immunomodulatory therapy DOI Creative Commons
Luisa F. Alviz, Benjamin Jones, Shruti Agnihotri

et al.

Therapeutic Advances in Infectious Disease, Journal Year: 2024, Volume and Issue: 11

Published: Jan. 1, 2024

Opportunistic central nervous system (CNS) infections are a significant cause of morbidity and mortality in immunocompromized patients, including those undergoing transplantation receiving immunomodulatory therapy. Particularly these individuals, the clinical presentation may have atypical patterns, emphasizing need to consider various diagnostic possibilities, noninfectious conditions. Quick accurate identification, along with prompt treatment, is crucial for improving patient outcomes. Therefore, understanding which pathogens likely infection based on factors such as timing post-transplantation, specific organ transplant, mechanism action medications essential. This review will provide detailed description types that arise context

Language: Английский

Citations

1
Impact of blood donation biovigilance and transfusion‐transmitted infections on organ transplantation DOI
Adam G. Stewart, Camille N. Kotton

Transplant Infectious Disease, Journal Year: 2024, Volume and Issue: 26(S1)

Published: June 27, 2024

Over 118 million blood donations are collected globally each year. Recipients of products include those who experience major trauma or surgery, have acute loss and anemia, impaired bone marrow function. Solid organ transplant recipients often require transfusion which places them at risk transfusion-associated adverse events including transfusion-transmitted infection. National hemovigilance networks documented low rates infection in the general population. Incidence continues to occur solid patients arises mainly from existing gaps donor biovigilance processes. Emerging infectious diseases highlighted donor-recipient pathway administering safe products. This article reviews current process regulatory oversight biovigilance, screening microbiological testing, highlights cases literature, addresses ways may be improved, with a focus on impact transplantation.

Language: Английский

Citations

0